Agreed. Cherry picking of stats. Just like Culper. As long as the new patients exceed the dropouts, then Daybue will continue to increase in sales. From memory, only about half the US market has been tapped, and let's not forget the rest of the world. This is an excellent result, but Daybue is only the tip of the iceberg for Neuren.
Acadia, page-239
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.71 |
Change
0.000(0.00%) |
Mkt cap ! $2.644B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 350 | $30.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.68 | 45 | 1 |
View Market Depth
| Last trade - 16.16pm 24/05/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable